Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

4.860 -0.130 (-2.61%)
Streaming Delayed Price Updated: 12:04 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 Next >
News headline image
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Host Business Update Call on November 12, 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Pricing of $40 Million Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Proposed Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESS Newswire
News headline image
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.